Recent Updates
Recently added Catalysts
PEPG Negative Sentiment Score: 20/100

PepGen Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPG

Key Takeaway: PepGen Inc. is facing a class action lawsuit for alleged securities law violations during the period from March 7, 2024, to March 3, 2025. The lawsuit claims that the company made false statements about its lead product candidate, PGN-EDO51, regarding its safety and effectiveness. Additionally, it is alleged that deficiencies in the CONNECT2 study could lead to a halt in its progress, potentially impacting the drug's commercial prospects. Shareholders are encouraged to register for participation in the class action.

Market Sentiment Analysis

CONCERNS & RISKS

  • Accusations of misleading statements regarding PGN-EDO51's effectiveness and safety.
  • Concerns that the CONNECT2 study may halt due to safety or regulatory issues.
  • The company’s public statements have been described as materially false and misleading.

Full Press Release Details

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG).
Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: March 7, 2024 to March 3, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company’s lead product candidate, PGN-EDO51, was less effective and safe than defendants had led investors to believe; (ii) phase two, CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration (“FDA”) approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51’s clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.
DEADLINE: August 8, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=159239&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of PEPG during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 8, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for PepGen Inc. shareholders?

The class period for PepGen Inc. shareholders is from March 7, 2024, to March 3, 2025.

What allegations are made against PepGen Inc.?

Allegations include misleading statements about the effectiveness of PGN-EDO51 and issues with the CONNECT2 study's safety for FDA approval.

When is the deadline to register for the class action?

The deadline to register for the class action is August 8, 2025.

Do shareholders need to be lead plaintiffs to participate?

No, shareholders do not need to be appointed as lead plaintiffs to partake in any recovery.

How can shareholders monitor their case status?

Registered shareholders will be enrolled in a portfolio monitoring software for status updates.

Last updated: Aug 4, 2025